Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Hims & Hers Health, Inc. stock is from April 29, 2025, to June 23, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Hims & Hers made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4]. - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings available to its subscribers [4]. - The lawsuit asserts that when the true details were revealed, investors suffered damages [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims & Hers Health, Inc. made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo and the implications for its subscribers' access to Wegovy and compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result of these misleading statements [4]

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, which has led to a significant drop in its stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit is titled Sookdeo v. Hims & Hers Health, Inc. and covers the period from April 29, 2025, to June 23, 2025 [1]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding patient safety [2]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices, which resulted in a more than 34% decline in Hims & Hers stock price [3]. Group 2: Lead Plaintiff Process - Investors who purchased Hims & Hers securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [4]. - The lead plaintiff is typically the investor with the greatest financial interest and must be typical and adequate of the class [4]. Group 3: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of illegitimate products and the collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy, which jeopardized patient safety and posed a risk to its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - Defendants are accused of failing to disclose that the communication with Novo Nordisk would not ensure a long-term collaboration for access to Wegovy for Hims subscribers [4]. - The complaint also claims that Hims misrepresented the approval of its compounded semaglutide products by Novo and made misleading statements about the availability of branded Wegovy alongside these products [4]. Group 3: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors in this class action lawsuit and encourages affected individuals to reach out for more information [5][6].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding the safety of its products [2][3]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices that jeopardized patient safety, leading to a stock price decline of over 34% [3]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Hims & Hers securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [4]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [4]. Group 3: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Insights - Regeneron Pharmaceuticals reported strong financial results for Q2 2025, with notable growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo, alongside multiple regulatory approvals [2][3][5] Financial Highlights - Total revenues for Q2 2025 reached $3.68 billion, a 4% increase from $3.55 billion in Q2 2024 [3][12] - GAAP net income was $1.39 billion, down 3% from $1.43 billion in the same quarter last year, while non-GAAP net income increased by 5% to $1.42 billion [3][12] - Non-GAAP net income per share rose 12% to $12.89, compared to $11.56 in Q2 2024 [3][12] Business Highlights - Dupixent global net sales increased by 22% to $4.34 billion, while EYLEA HD U.S. net sales grew by 29% to $393 million [5][12] - The FDA approved Lynozyfic for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria [5][10] - The company has approximately 45 product candidates in clinical development, with significant progress in its oncology portfolio [4][5] Regulatory and Pipeline Updates - The FDA accepted for priority review Libtayo's supplemental Biologics License Application for adjuvant cutaneous squamous cell carcinoma, with a target action date in October 2025 [10][11] - The company reported interim results from the Phase 2 COURAGE trial, showing promising data for obesity treatment [10][11] Capital Allocation - Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends, while committing over $7 billion to U.S. manufacturing investments and business development since the start of 2025 [3][23] - A cash dividend of $0.88 per share was declared, payable on September 3, 2025 [24]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the implications for Hims subscribers' access to the weight-loss drug Wegovy [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Hims & Hers Health, Inc. and Sarepta Therapeutics, Inc. due to alleged misleading statements and undisclosed material facts regarding their business operations and prospects [1][4]. Hims & Hers Health, Inc. (NYSE: HIMS) - Class period is from April 29, 2025, to June 23, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion of illegitimate versions of Wegovy, risking patient safety and jeopardizing collaboration with Novo Nordisk [2][3]. - Defendants are accused of making false statements about the partnership with Novo, which was supposed to ensure access to Wegovy for Hims subscribers, and misrepresenting the offerings of compounded semaglutide products [3]. Sarepta Therapeutics, Inc. (NASDAQ: SRPT) - Class period is from June 22, 2023, to June 24, 2025, with a lead plaintiff deadline of August 25, 2025 [4]. - The complaint alleges that Sarepta misled investors about the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [4]. - Specific allegations include failure to disclose significant safety risks associated with ELEVIDYS, misleading statements about trial protocols, and the potential for regulatory scrutiny due to adverse events [4]. - Following a safety update on March 18, 2025, where a patient died after treatment, Sarepta's stock price fell by $27.81 per share, or 27.44% [5]. - Subsequent disclosures of additional patient deaths led to further declines in stock price, including a drop of $15.24 per share, or 42.12%, on June 15, 2025 [6].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the weight loss drug Wegovy®, resulting in a significant drop in its stock price after the termination of its partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the Class Period, Hims & Hers made false and misleading statements and failed to disclose material facts, including engaging in deceptive promotion of illegitimate versions of Wegovy® [4]. - The lawsuit also alleges that there was a significant risk of Novo Nordisk terminating its collaboration with Hims & Hers due to these deceptive practices [4]. Group 3: Impact of Events - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing concerns over patient safety due to the deceptive promotion of knockoff versions of Wegovy® [5]. - Following the announcement of the partnership termination, Hims & Hers shares fell more than 34% [5].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to deceptive practices in promoting and selling medications [1][2][3] Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4] - Allegations include that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety [2][3] - Following the termination of its partnership with Novo Nordisk due to these allegations, Hims & Hers' stock price dropped by over 34% [3] Group 2: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2] - The company announced a collaboration with Novo Nordisk on April 29, 2025, which was later terminated due to the aforementioned allegations [2][3] Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud and shareholder litigation [5] - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone, and has been ranked 1 in securing monetary relief for investors [5]